Term
| gout result of metabolism of |
|
Definition
|
|
Term
| gout diseasei sm ot commonly dueto |
|
Definition
| lack of clearance , (as opposed to overproduciton) |
|
|
Term
|
Definition
| inhibits tuublin polyermization into microttubules, , inhibitsl uekocyte miraiton nad phagocytosis |
|
|
Term
| colchicine method of takign |
|
Definition
| oral. used for acute attacks |
|
|
Term
|
Definition
lots (not mentioned: nause vomitting abdmoinal pain, burning throat patin , blodo idarrhea, shock hematuria, and oliuria).
no logner first lien agnets due to toxicities. |
|
|
Term
|
Definition
|
|
Term
|
Definition
| used for acute gout, msot popular nsaid. |
|
|
Term
|
Definition
| inhbits cox mediated PG syntehsis |
|
|
Term
|
Definition
| nsaid that also icnerases uric acid excreiton in urine |
|
|
Term
| oxaprozin adverse effects |
|
Definition
| will make kdiney stones worst if you dont be careful |
|
|
Term
|
Definition
|
|
Term
|
Definition
|
|
Term
|
Definition
| increase sectiona nd decerase reabsortion of uric acid (organic acids haat act at the anion tranprot sites of proximal tubules |
|
|
Term
| uricosuric agetns advantags |
|
Definition
| in tophagcoues depsotis iwl lstimualte rebosrption of the tophi. |
|
|
Term
| uricosuric agents interactions |
|
Definition
| aspirin- inhibits secretory urate transporter |
|
|
Term
| uricosuric agnets indications |
|
Definition
| for CHronic NOT acute. expectation tobe taken for a long period. used in aptients iwth frequent attacks, patients with tophaceous gouts- excellent for this, but useful only for udnerexcretors. |
|
|
Term
| uricosuric agents adverseeffects |
|
Definition
dont use in patients who over excrete or even excrete nromal elvels of urate, otherwise will predispose to uric acid stones. NEed to keep ph alkaline and urinate frequently.
no basis for choosing on drug over antoehr. Irritating to gut. Take with food and divided dose |
|
|
Term
|
Definition
| irreversible antagonist of xanthien oxidase (purine analog) |
|
|
Term
|
Definition
| irreversible antagonist of xanthien oxidase (nonpurine) |
|
|
Term
| xanthine oxidase inbhitior |
|
Definition
intercrises agent, the preffered agent for chronic gout therapy. Chronic tohgacous gout (can dissovle tophi more rapidly than uricosurics). These will cork with renal stoen aptients. also useful for patients with renal impairement.
taken for years and life. |
|
|
Term
| aloppurinol blocker adverse effects |
|
Definition
| acute gouty attacks due to intial flare occuring when urate crystals are beign withdran form tissues. Initaited with colchicine or an nsaid (indomeathicn , until steady state seru mruaret e is nromalized to lese than 6 mg/dl. Gi irriation, take with foodas |
|
|
Term
| allopurinol specific s9de effects |
|
Definition
allopurinol is less preferred to febuxostat due to unique adverse effects.
necrotizing vasculitis, aplastic anemia, hepatic toxicity, itnerstial neprhitis. rarely cataracts.
MSOT COMMON: ALLERGIC SKIN REACTIONS: toxic epidermal necrolysis. - STevens johnsons syndrome.
Drug itneractions: ltos of drus inlucindg mercapturopine, warfarin. |
|
|
Term
| febuxsostat vs. allopurinol |
|
Definition
| febuxostat much better tolerated in patients with allpuoruinol intoelrance. |
|
|
Term
|
Definition
| inhibits cox IRREVERSIBLY. platelet is inactivated for hte lifetime of the platelet. |
|
|
Term
| cox 1 vs. cox 2 in thrombosis |
|
Definition
cox 1 is foudn in paltelets , inhibit cox-1 and formaiton of thormobxan a 2 and thrombosis.
this shifts balance to cox-2 in endothelium. Cox 2 in endothelium leads to prostacyclin produciton which reduces thrombosis. |
|
|
Term
| cox 2 inbhiitors problems |
|
Definition
| you inhibit, cox2= upregulatio nfo cox1 leadign to thormbosis |
|
|
Term
| pharm properties of nsaids |
|
Definition
antiinflammtory=- mediated primarily through cox-2 inhibition of prostaglandin biosyntehsis.
Anaglesic activity- mediated thorugh inhibition of prostaglandin biosyntehsis centrally and locally.
antipyrertic activity- prverntion of pge2 syntehsis.
prolongation fo bleeding time- inbhition fo cox-1 i npaltelets = decrsaed txa2 |
|
|
Term
| naproxen/ibuprofen vs aspirin |
|
Definition
| iburporfen has logenr halflives |
|
|
Term
|
Definition
| dhfr inhbitior. inhibting producers of dna syntehsis, reducing inflammatory cells |
|
|
Term
| methotrexate adverse effects |
|
Definition
| foalte deficiency, folic acid supplemeantion, contraindicatedi n rpegnancy |
|
|
Term
|
Definition
| rhumeatoid arhtiritis as wel las other inflammatory disorders |
|
|
Term
|
Definition
| pyrimidien syntehsis inbhitiors |
|
|
Term
| leflunomide pharamcokientics |
|
Definition
|
|
Term
| leflunomide adverse effects |
|
Definition
| teratogenic, stop 2 yeears prior pregnancy |
|
|
Term
| hydroxycloroquine adverse effects |
|
Definition
| requries 3-6 months for benefit, may due retinal damage |
|
|
Term
|
Definition
|
|
Term
|
Definition
| usefulf or RA but litmited use logn term due to toxicity. |
|
|
Term
| etanrecept moa and mode of adminsitration |
|
Definition
| protein so has to be adminsitered IV. Binds to TNF alpha with high affinity. (it is a receptor nto an antibody) |
|
|
Term
|
Definition
| synergistic with methotrexate |
|
|
Term
|
Definition
| antibody to tnfalpha. reduces blodo elvel of tnfalpha. |
|
|
Term
|
Definition
| fully human antibody to tf as opposed to inflixmab, decreawsed immuen resposne of host. |
|
|
Term
| glucorticoicds vs. nsaids |
|
Definition
glucocorticoids inhibit formation fo aarachidonate from phospholipids, (vi inhibtion o PLA2).
NSAIDs= inhibition of formaiton of arachidonate to prostaglandin vis inhibition of cox |
|
|
